Eli Lilly blows past estimates, hikes sales outlook on resilient Zepbound and Mounjaro demand - CNBC
Source: CNBC ·
Eli Lilly blows past estimates, hikes sales outlook on resilient Zepbound and Mounjaro demand CNBCLilly Raises Sales Guidance, Widening Its Lead in Obesity Market BloombergEli Lilly lifts revenue outlook on weight-loss drug sales, trims profit view on deal charges Reuters3 Big Pharma Earnings Reports to Watch: Eli Lilly, Merck and Gilead Yahoo FinanceAhead of Eli Lilly Earnings, Here's What…
BestAIBroker analysis
- Finance-aware sentiment: positive (+0.80 on a -1 to +1 scale).
- Event classification: GUIDANCE.
- Market importance score: 42/100, weighting entity relevance, source credibility, multi-outlet coverage and recency.
- Symbols referenced: LLY.